Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Delivery of Nyloxin™ to New Vitality
August 29, 2013

Nutra Pharma has completed their first delivery of the Company’s homeopathic pain reliever, Nyloxin®, to their newest distributing partner, New Vitality.

August 29, 2013 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has placed and received their first order of the Company's all-natural, non-addictive pain reliever, Nyloxin®. The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product.

“This radio test represented the first broad exposure to our Nyloxin brand,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. “It's been a pleasure working with New Vitality as they create awareness for our products," he continued. "The radio advertising ran in major markets across the US over several weeks, with a consumer response that was positive enough to warrant the first orders from New Vitality. As things progress, we expect to expand the relationship and have already worked with New Vitality on our launch of Pet Pain-Away, our product for pain in companion animals," concluded Mr. Deitsch.

Nyloxin™ is a homeopathic drug that utilizes proteins from cobra venom to relieve pain and inflammation. An analgesic that began gaining U.S. attention in 1936, cobra venom’s effects in minute doses have been shown by researchers to be superior to that of morphine, a highly addictive opiate.  The product is available in an easy-to-use oral spray for treating: lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, as well as a topical gel for treating: repetitive stress, arthritis and joint pain. Nyloxin™ is also available in Extra Strength formulations.

Additional benefits to Nyloxin™ include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• Long-Lasting

For the past 16 years New Vitality (www.newvitality.com) has helped people live longer and look younger by marketing and selling vitamins, health supplements, and personal care products. Customers learn about their products from advertisements which use celebrities, sport athletes and doctors to promote them on over 2000 radio and television stations nationwide. New Vitality’s catalog contains over 150 items which range from energy supplements to fruit and vegetable supplements to colon cleanses and products for men’s health.

A recent interview conducted by Christopher Castaldo, the CEO of Wall Street Buy Sell Hold (www.wallstreetbuysellhold.com) with Jonathan Flicker, the CEO of New Vitality can be viewed at:
http://tinyurl.com/JF-interview

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com and www.Nyloxin.net

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The delivery of Nyloxin to New Vitality should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics